Sentences with phrase «patients in clinical trials»

Some patients in clinical trials experienced symptoms such as nausea, headaches, and mild weight loss.

Residents fill a key role in providing compassionate clinical patient care under the supervision of a faculty member, and the medical care of patients in clinical trials.

Neither drug is on the market yet, but patients in clinical trials have shown some small improvements.

www.DupCheck.org is a web - based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas.

Fred Hutchinson Cancer Research Center on Tuesday announced the official opening of a first - of - its - kind clinic dedicated to providing immunotherapies for cancer patients in clinical trials.

These laboratories offer an ever - expanding menu of internationally harmonized tests to support the stratification and enrollment of patients in clinical trials, optimized treatments, and development of companion diagnostics (CDx).

Building on this breakthrough research, the researchers sought to translate that discovery into a practical prognostic test that doctors could use to assess care and enroll patients in clinical trials.

Over 1,700 cellular products have been administered to > 600 patients in clinical trials since 1996.

«Currently, about 80 percent of patients in these clinical trials provide no useful information,» says Dr. Krolewski.

Since breast cancer treatment in older patients is mostly not evidence - based due to poor inclusion of older patients in clinical trials, we propose that studies investigating breast cancer treatment are much more important than breast cancer screening in this population and should be prioritised.

Finally, the bill restricts travel by Collins and his staff until the NIH implements a pilot study on the medical - insurance coverage of patients in clinical trials that was requested by Congress last year.

Gentzsch noted potential reasons to explain why patients in the clinical trial saw benefit from the two drugs even though her team's lab experiments produced evidence to the contrary.

Patients in the clinical trial who got the combined therapies also had fewer serious adverse side effects than those who received only ipilimumab, the researchers report in the Journal of the American Medical Association.

Dr. Kohn will begin enrolling patients in the clinical trial within the first three months after receiving the CIRM grant.

Dr. Gonzalo Pizarro, one of the first authors on the study, comments that «it has been possible to demonstrate the beneficial and sustained effect of this acute treatment thanks to the realization of advanced cardiac magnetic resonance analysis of almost all the patients in this clinical trial.»

Makkar began the study when a high - resolution imaging study of one of the patients in a clinical trial who had stroke showed clot formation on the aortic valve leaflets that open and close to regulate the flow of blood.

That clearance would be a high - water mark for gene therapy research, which suffered a major setback in 1999 with the death of a patient in a clinical trial for a liver disorder.

The new treatment may not work for for your pet, even if it benefits other patients in the clinical trial.

Participation of animal patients in a clinical trial does not increase the owner's cost for the care of their animal.

Not exact matches

«Watson is able to give us faster, better matching of patients to potential clinical trials that our oncologists wouldn't have otherwise be able to see — and I sit with our oncologists who work on this kind of thing,» Christopher Ross, CIO at the Mayo Clinic, told MobiHealthNews in an interview.

In health care, this amounts to an hourly avalanche of new research papers, clinical trials, scientific studies, and patient health information.

What this all hopefully adds up to is a smarter clinical trial — one that doesn't ignore the reality of the patients involved in it.

With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned — which could be the single biggest factor in speeding up drug development.

Participants in United Therapeutics» clinical trials now have their genomes sequenced and researchers at the company plan to correlate patient outcomes with that genomic sequence data.

Among them: «a lack of data standards in treating cancer, lack of data sharing in the research and development enterprise, lack of patient input and participation in clinical trials,» and more.

Kite Pharma, one of the companies chasing a new generation of cancer drugs called chimeric antigen receptor T - cell (CAR - T) therapies, announced a patient death in a clinical trial of its experimental KTE - C19.

• Mendel.ai, a startup that connects cancer patients with clinical trials, raised $ 2 million in seed funding from DCM Ventures, Bootstrap Labs and Launch Capital, according to TechCrunch.

The company points to a simple resource allocation problem that's hindered the most effective patient care: the fact that it is physically impossible for oncologists to keep track of every study, every clinical trial, and every breakthrough in the wildly stratified world of cancer research.

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

In clinical trials, patients» sight was assessed by their ability to navigate an obstacle course in different levels of lighIn clinical trials, patients» sight was assessed by their ability to navigate an obstacle course in different levels of lighin different levels of light.

In a surprising twist, Merck's anacetrapib, a heart disease drug, produced strong results in a large clinical trial of 30,000 patients, according to the companIn a surprising twist, Merck's anacetrapib, a heart disease drug, produced strong results in a large clinical trial of 30,000 patients, according to the companin a large clinical trial of 30,000 patients, according to the company.

Merck took a precision approach and targeted its medication towards patients whose tumors express the PD - L1 protein, enrolling these individuals in clinical trials.

Besides randomized controlled clinical trials, there are a number of ways researchers can study how a particular cancer treatment is playing out in the real world: there are retrospective studies, observational studies, and even prospective research done using patient registries.

Intarcia has completed several late - stage clinical trials in which it uses the pump to deliver a glucose - controlling drug continuously for months — an idea, that if successful (and approved by the FDA) could significantly help patients with type 2 diabetes, fewer than half of whom maintain the recommended glycemic levels.

But a late - stage clinical trial called CheckMate - 026 for the drug failed to meet its primary goal of halting cancer progression in advanced, untreated patients whose tumors consisted of at least 5 % PD - L1.

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

Many have used this data in designing new methods to supplement and even replace clinical trials, which are notoriously difficult to fill with patients.

In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatmenIn clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatmenin some cases eliminating all signs of the cancer in patients six months after treatmenin patients six months after treatment.

GUMC says its researchers are now planning larger clinical trials with nilotinib for patients with Parkinson's and other similar diseases including Alzheimer's disease, likely to begin in 2016.

Omecamtiv mecarbil is the subject of GALACTIC - HF, an international Phase 3 clinical trial in patients with heart failure.

That's particularly significant since people with diabetes have a significantly higher risk of developing cardiovascular conditions — and Lilly's drug was shown to cut the cardiovascular - related deaths in diabetes patients by a staggering 38 % in clinical trials.

The company's lead product candidate, dilanubicel (NLA101), is currently being evaluated in two ongoing Phase 2 clinical trials in adult and pediatric patients with hematologic malignancies undergoing an allogeneic transplant and adult patients receiving high dose chemotherapy for Acute Myeloid Leukemia.

While Yervoy brought in $ 960 million in sales in 2013 (an enormous figure for a two - year - old drug with a small patient population), the company currently has more than 35 ongoing clinical trials investigating another drug that disengages the immune system's brakes: the much - awaited nivolumab, which was also from the Medarex portfolio.

The case was yet more evidence that both the clinical trial doctors and the drug's developers would have to be more patient in assessing this new type of therapy.

Amarin's clinical development program for Vascepa includes a trial known as the REDUCE - IT cardiovascular outcomes study, an 8,175 - patient study commenced in 2011.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Announced a clinical trial collaboration with Pfizer, Inc. (Pfizer) to evaluate the safety and efficacy of the investigational combination of Yescarta and Pfizer's utomilumab, a fully humanized 4 - 1BB agonist monoclonal antibody, in patients with refractory large B - cell lymphoma.

«The positive efficacy results observed in the pivotal phase 3 clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne,» said Allergan R&D chief David Nicholson in a statement.

Identifying resistance mechanisms and creating non-invasive tests to aid in the selection and monitoring of patients during clinical trials.

BioNTech hit the headlines in July when its experimental personalized cancer vaccine, tailored to the tumors of individual patients, kept disease in check in an early - stage clinical trial.